The HHS Office for Civil Rights said it will start compliance reviews for four medical schools after antisemitic incidents ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Matthew Moll, MD, MPH, and Michael H. Cho, MD, MPH, from the Department of Medicine at Brigham and Women's Hospital are ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an ...

Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Hypercalcemia Treatment MarketThe global hypercalcemia treatment market is on track for significant growth, with an estimated valuation of USD 18.07 billion in 2023. The market is projected to expand ...